Launch Date
10/07/2020
Credit Amount
0.00 Expired
Credit Expires
10/07/2021
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, projected to affect 12 million Americans by 2030. However, a significant number of AF cases, particularly non-valvular atrial fibrillation (NVAF) remain undiagnosed, putting patients at risk for severe cardiovascular (CV) complications, including increased risk of stroke. It is imperative that clinicians identify the symptomatology of AF and effectively diagnose NVAF, as these complications can potentially be avoided by increased screening and guideline-directed anticoagulation treatment. Unfortunately, despite the fact that both opportunistic and systematic screening have been shown to be effective in detecting NVAF, clinicians often lack knowledge of the available tools and strategies for implementing it, particularly in primary care settings.
This CME Outfitters Live and OnDemand webcast will feature expert faculty addressing the impact of undiagnosed NVAF, the benefit and use of screening tools for early detection, best practices for optimizing screening, implementing oral anticoagulant therapy for stroke prevention, and the use of digital health technologies, with a goal of fostering collaborative care and optimizing patient outcomes.
At the end of this CME/CE activity, participants should be able to:
The following learning objectives pertain only to those requesting CNE or CPE credit:
Supported by an educational grant from the Bristol-Myers Squibb and Pfizer Alliance.
Primary care physicians, cardiologists, nurse practitioners, PAs, nurses, and pharmacists.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Bhatt reports he is a consultant for Abbott; Afimmune; Amarin Corporation; Amgen Inc.; Astra Zeneca; Bayer Corporation; Boehringer Ingelheim; Bristol-Myers Squibb Company; Cardax, Inc.; Chiesi USA, Inc.; CSL Behring; Eisai Inc.; Ethicon USA, LLC; Ferring Pharmaceuticals: Forest Laboratories; Fractyl Laboratories, Inc.; Idorsia Pharmaceuticals Ltd; Ironwood Pharmaceuticals, Inc.; Ischemix; Lexicon Pharmaceuticals, Inc.; Lilly USA, LLC.; Medtronic; PhaseBio Pharmaceuticals, Inc.; Pfizer Inc.; PLx Pharma Inc.; Regeneron; Roche; Sanofi-Aventis U.S. LLC; Synaptic Pharmaceutical Corp.; and The Medicines Company.
Dr. Cannon reports that he receives research grants from Amgen Inc.; Boehringer-Ingelheim; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; and Pfizer Inc. He is a consultant for Aegerion Pharmaceuticals, Inc.; Alnylam Pharmaceuticals ,Inc.; Amarin Corporation; Amgen Inc.; Applied Therapeutics; Ascendia Pharmaceuticals; Boehringer-Inghelheim; Bristol-Myers Squibb Company; Corvidia; Eli Lilly and Company; HLS Therapeutics Inc.; Innocent Biologics, Inc.; Janssen Pharmaceuticals, Inc.; Kowa Pharmaceuticals America, Inc.; Merck & Co., Inc.; Pfizer Inc.; Rhoshan Pharmaceuticals, Inc.; and Sanofi-Aventis.
Dr. Savoy has no disclosures to report.
Jeffrey Helfand, DO (peer reviewer) has no disclosures to report.
Mae Ochoa, RPh (peer reviewer) has no disclosures to report.
Evan Luberger (planning committee) has no disclosures to report.
Rachel Speer, PhD (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.
NOTE: Pharmacist CE Universal Activity Number, Enduring: 0376-0000-20-121-H01-P.
Call us at 877.CME.PROS (877.263.7767).
TV-120-100720-90